




(a)




(b)




(c)



(d)




(e)



(f)

Supplementary Figure S1. Bland–Altman plot comparing non-invasive liver fibrosis screening tools in class 3 obesity. (a) FIB-4 Index and APRI; (b) FIB-4 Index and NFS; (c) FIB-4 Index and FAP Index; (d) APRI and NFS; (e) APRI and FAP Index; (f) NFS and FAP Index. APRI: AST (Aspartate Aminotransferase) to Platelet Ratio Index; EQI: ElastQ Imaging; FAP: Fibroblast Activation Protein; FIB-4: Fibrosis-4; NFS: NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score.



Supplementary Figure S2. Area under receiver operating characteristics curves (AUROC) of 2D-SWE, FIB-4 index, APRI, FAP index values for detecting risk of significant/advanced fibrosis ($F \geq 2$). 2D-SWE: 2D-Shear Wave Elastography; APRI: AST (Aspartate Aminotransferase) to Platelet Ratio Index; FAP: Fibroblast Activation Protein; FIB-4: Fibrosis-4.